Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin

Core Insights - Dyadic Applied BioSolutions and Proliant Health & Biologicals have launched AlbuFree™ DX, a recombinant human albumin product utilizing Dyadic's proprietary technology, marking a significant step in Dyadic's commercialization strategy [1][2][3] Company Overview - Dyadic is a global biotechnology company focused on producing precision-engineered, animal-free proteins and enzymes for various applications, including life sciences and nutrition [1][5] - Proliant is a leading global producer of purified proteins, including albumin, serving life science and diagnostic markets with a well-established distribution network [1][6] Product Launch - The launch of AlbuFree™ DX highlights Dyadic's commitment to recombinant protein products with established commercial pathways and market demand [2][3] - AlbuFree™ DX is positioned to meet the rising demand for animal-free inputs in cell culture and life science applications, representing a key milestone in Dyadic's portfolio [3][4] Strategic Partnership - Under the agreement, Dyadic will receive a share of profits from Proliant's sales of recombinant human albumin products, reinforcing the partnership's commercial viability [2][4] - Proliant's extensive experience in albumin production and distribution supports the successful integration of AlbuFree™ DX into the market [4] Future Developments - Dyadic plans to expand its portfolio of recombinant proteins for various applications through internal programs and strategic partnerships, indicating a focus on scalable commercialization [4]